Catheter fracture : a0 rare complication of totally implantable subclavian venous access devices
Currently, Cathflo Activase is the only FDA-approved agent indicated for use in venous access devices
obstructed by thrombus.
Catheter occlusion is the most common noninfectious complication seen with long-term central venous access devices
Central venous access devices
are being used more frequently as many critical medical therapies require their use.
This independent study offering is designed for nurses and other health care professionals who care for and educate adult patients regarding central venous access devices
markets for venous access devices
including peripherally inserted central catheters (PICCs), central venous catheters (CVCs), dialysis catheters, implantable ports, and catheter securement devices.
A recently published article on the care and maintenance of central venous access devices
describes the benefits of intraluminal protection connectors for preventing catheter-related bloodstream infections (CR-BSI).
2Nurse's guide to understanding and treating thrombotic occlusion of central venous access devices
In a separate paper, Janice Gabriel, MPhil, PgD, BSc (Hons), RN writes about the British experience with StatLock for securement of intermediate to long-term venous access devices
The Genentech Lytic Portfolio of clot-busting agents includes Activase(R) (alteplase, recombinant) tissue plasminogen activator (t-PA) for acute ischemic stroke, TNKase(R) (tenecteplase) for acute myocardial infarction, and Cathflo Activase(R) (alteplase, recombinant) for restoration of function to central venous access devices
occluded by blood clots.